148
Views
17
CrossRef citations to date
0
Altmetric
Review

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia

, , , &
Pages 2263-2266 | Published online: 29 Oct 2018

Abstract

Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added to statin therapy it has been shown to cause a significant incremental LDL-C reduction, leading to a reduction of cardiovascular risk. Evolocumab has a favorable side effect profile, and its self-administration at home appears to be safe and effective with the appropriate training and instructions from a health care provider. Current studies are showing encouraging results regarding adherence to evolocumab in real-life settings, and adherence rates to evolocumab appear to be better than those to statins. However, further larger studies are needed for a more definitive assessment of the short- and long-term patient adherence rates to evolocumab. In addition, reductions in the price of evolocumab may also be necessary to improve cost-effectiveness of the drug.

Introduction

Extensive evidence shows that low-density lipoprotein cholesterol (LDL-C)-lowering therapy has beneficial effects in decreasing cardiovascular risk in both primary and secondary prevention.Citation1Citation4

Statins are the standard of care for LDL-C lowering; however, several patients develop statin intolerance due to side effects, especially myalgias and weakness.Citation5,Citation6 Furthermore, even with high-intensity statin therapy, some patients cannot achieve the desired LDL-C goal, and therefore remain at high risk for cardiovascular events.Citation7,Citation8 Because of that, extensive research has been conducted to find additional agents with an acceptable side effect profile that could cause significant reduction of LDL-C levels.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a relatively new class of LDL-C-lowering agents, which act by blocking the activity of PCSK9 and thus reducing the degradation of LDL receptors and increasing the clearance of LDL-C.Citation9Citation11 Evolocumab is a monoclonal antibody which inhibits PCSK9 and is administered subcutaneously in biweekly or monthly intervals. In the FOURIER trial, which had a follow-up period of 2.2 years, evolocumab, when added to the statin therapy, was shown to cause an additional reduction of LDL-C levels by 59%. More importantly, evolocumab decreased the composite of cardiovascular death, myocardial infarction, or stroke by 20%.Citation12

Notwithstanding, the benefits of the treatment with evolocumab will only be replicated in real-life if patients accept, adhere, and comply with the prescribed treatment regimen. It would be very important here to point out that in the case of statins, their real-life effectiveness is significantly compromised by poor adherence and compliance.Citation13Citation15

Thus, our review aims to focus on patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia.

Patient adherence and compliance

Medication compliance is the act of taking medication on schedule or taking medication as prescribed; however, recently, this term has fallen into disfavor. Medication adherence is the act of filling new prescriptions or refilling prescriptions on time, and this term better represents the more complex interplay among patient, provider, and medication and reflects the fact that following a medication regimen is not necessarily a simple choice.Citation16

The lack of adherence to cardiovascular medications in real-life settings leads to poor clinical outcomes, as it increases the risk for hospitalization and mortality, particularly in high-risk patients.Citation17,Citation18

With regard to statins, it is well established that statin therapy decreases mortality in high cardiovascular risk patients in both primary and secondary prevention.Citation19,Citation20 However, studies have reported poor adherence to statin therapy, which has been attributed to the patients’ lack of knowledge about the efficacy of the statin therapy, statin intolerance, or fear about possible side effects.Citation21,Citation22 Here, it has to be stressed that poor adherence and compliance to statins come with a heavy toll, as they lead to significant increases in total mortality, as well as cardiovascular morbidity and mortality.Citation13Citation15

In this context, due to its acceptable side effect profile, reduced dosing frequency, and the availability of easy-to-use and effective devices for self-administration, evolocumab brings opportunities to improve the adherence to lipid-lowering therapy. Here it has to be mentioned that, in contrast to other drug classes (eg, antiplatelet agents, the effect of which is not easy to routinely monitor), monitoring of adherence to PCSK9 inhibitors is a relatively easy task in view of their profound LDL-C-lowering effect.

In this regard, studies have shown overall satisfactory results with respect to patient’s adherence to PCSK9 inhibitors (including evolocumab) in real-life settings. More specifically, in a small retrospective analysis, the level of full adherence to PCSK9 inhibitors was found to be higher than statins (79.4% vs 30.9%, respectively), although the difference did not reach statistical significance due to the small number of subjects.Citation23 In another small study, which examined the real-world effectiveness and safety of PCSK9 inhibitors (evolocumab and alirocumab), the LDL-C reductions obtained with PCSK9 inhibitors in clinical practice were found to be similar to those described in clinical trials (50%–70%). PCSK9 inhibitors were well tolerated and there were no discontinuations due to side effects.Citation24

Thus, based on the above, evolocumab appears to be in general well tolerated, effective, and with a low rate of reported side effects. However, in-depth patient education, close supervision, and regular follow-up are strongly recommended in order to optimize adherence and compliance to therapy.Citation25,Citation26

Notwithstanding, even though current studies are showing encouraging results regarding adherence to evolocumab (and PCSK9 inhibitors in general) in real-life settings, there are still insufficient data and further larger studies are needed to evaluate the short- and long-term patient adherence rates to these medications.

Acceptability and perspective on evolocumab therapy

While evolocumab is available only via subcutaneous administration, studies have revealed that the self- administration of evolocumab at home is safe and effective with the appropriate training and instructions from a health care provider. More specifically, patients were successful in self-administering evolocumab in the home-use setting in approximately 95% of attempts and achieved LDL-C reductions from baseline to week 6 or the mean of weeks 10 and 12 of approximately 65%. Rates of successful self-administration and LDL-C reduction were similar across dosing schedules and study devices.Citation27

Furthermore, the choice of the monthly (QM) or twice weekly (Q2W) dosing regimen does not appear to be associated with any significant differences in adherence, acceptability or patients’ preferences. In a study, which included 2,318 patients (59% initially randomized to the QM regimen and 41% initially randomized to the Q2W regimen), 74% of those initially randomized to the QM regimen chose to continue with QM dosing and 26% decided to switch to the Q2W regimen. Similarly, from those initially randomized to the Q2W regimen, 70% chose to continue with Q2W dosing and 30% opted to switch to QM dosing. Only 2% of patients in the QM regimen and 2% of patients in the Q2W regimen did not receive any further doses following the first day of administration. More importantly, following initial decisions regarding dosing preference, patients did not generally choose to change their regimen further during ongoing treatment, as only 5% of QM patients and 8% of Q2W patients switched to the alternative dosing regimen.Citation28

One of the main barriers for patient’s access and appropriate continuation of the evolocumab therapy is the difficulty in obtaining insurance coverage, which is mostly due to the high cost of the medication. Studies have indicated a mean annual wholesale price for evolocumab as high as $14,100 and have reached the conclusion that assuming 2015 prices, PCSK9 inhibitor use in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease did not meet generally acceptable incremental cost-effectiveness thresholds and was estimated to increase US health care costs substantially.Citation29 This was confirmed by another recent study, which showed that at current prices, the addition of PCSK9 inhibitors to statin therapy was estimated to provide an additional quality-adjusted life year for $337,729 and that significant discounts were necessary to meet conventional cost-effectiveness standards.Citation30,Citation31 On the other hand, the National Institute for Health and Care Excellence in the UK has approved the limited use of PCSK9 inhibitors in certain high-risk patient groups, although these National Institute for Health and Care Excellence results were based on undisclosed price discounts negotiated with the pharmaceutical companies.Citation31,Citation32 In a recent study, which examined the cost-effectiveness of PCSK9 inhibitors vs ezetimibe through LDL-C reductions in a Norwegian setting, it was shown that high lifetime costs of PCSK9 inhibitors may not be offset by estimated health gains for most eligible patients, and PCSK9 inhibitors were found to be cost-effective only in secondary prevention for older patients with high absolute risk of cardiovascular disease. However, the authors did point out that this picture was likely to change as price of this class of medications decreases.Citation33 Finally, in a very recent Canadian study, despite the critical assumption that evolocumab may reduce mortality over time, it was shown that the drug was unlikely to be cost-effective for secondary prevention at current Canadian prices.Citation34

Given the above, the treatment with evolocumab presents an initial therapy coverage denial by insurance companies as high as 80%, even when the US Food and Drug Administration-approved indications for the therapy have been met by the patient. Furthermore, only 46.6% of Medicare patients and 26.7% of privately insured patients subsequently gained approval after extensive appeals.Citation35

In order to improve cost-effectiveness, the manufacturer of evolocumab offered a money-back guarantee by fully refunding the drug’s cost, under certain conditions, if a patient being treated with evolocumab is hospitalized with either a myocardial infarction or stroke. However, despite this improved outcomes-based pricing, the incremental cost-effectiveness ratio for a PCSK9 inhibitor added to a statin was only marginally improved. Even in the best scenario, in which the manufacturer would refund drug costs plus inpatient costs for myocardial infarction or stroke, the incremental cost-effectiveness ratio for a PCSK9 inhibitor added to a statin improved by only 3.1%.Citation36

Conclusion and future directions

From the above data, it becomes evident that evolocumab is a promising PCSK9 inhibitor that causes significant LDL-C reductions and decreases cardiovascular risk. Although current studies are showing encouraging results regarding adherence to evolocumab in real-life settings, further larger studies are needed for a more definitive assessment of the short- and long-term patient adherence rates. In-depth patient education, close supervision, and regular follow-up are important factors to optimize adherence to therapy. Reductions in the price of evolocumab may also be necessary to improve cost-effectiveness of the drug.

Inclisiran is a long-acting small interfering RNA (siRNA) molecule directed against PCSK9, and it has been shown to significantly decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels.Citation37 This agent is not licensed as yet and has not been proven to reduce cardiovascular outcomes, as of now. However, inclisiran appears very promising and, in the future, if approved, its use may lead to a significant improvement in adherence and compliance due to its very infrequent, 6-monthly dosing intervals.

Disclosure

Dr Constantine E Kosmas reports personal fees from Amgen, outside the submitted work. Dr Eliscer Guzman reports personal fees from Amgen Inc., outside the submitted work. Dr Kosmas and Dr Guzman are members of the Dyslipidemia Speaker Bureau of Amgen, Inc. The authors report no other conflicts of interest in this work.

References

  • Vallejo-VazAJRobertsonMCatapanoALLow-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-UpCirculation2017136201878189128877913
  • ReinerŽStatins in the primary prevention of cardiovascular diseaseNat Rev Cardiol201310845346423736519
  • KoskinasKCSiontisGCMPiccoloREffect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trialsEur Heart J201839141172118029069377
  • GrundySMPromise of low-density lipoprotein-lowering therapy for primary and secondary preventionCirculation2008117456957318227397
  • CohenJDBrintonEAItoMKJacobsonTAUnderstanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin usersJ Clin Lipidol20126320821522658145
  • ReinerZResistance and intolerance to statinsNutr Metab Cardiovasc Dis201424101057106624996502
  • RidkerPMMoraSRoseLJUPITER Trial Study GroupPercent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agentsEur Heart J201637171373137926916794
  • WongNDChuangJWongKPhamANeffDMarrettEResidual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009–2010)Am J Cardiol2013112337337923642513
  • PageMMWattsGFPCSK9 inhibitors – mechanisms of actionAust Prescr201639516416727789927
  • ReinerŽPCSK9 inhibitors – past, present and futureExpert Opin Drug Metab Toxicol201511101517152126329686
  • ReinerŽPCSK9 inhibitors in clinical practice: Expectations and realityAtherosclerosis201827018718829366497
  • SabatineMSGiuglianoRPKeechACFOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseN Engl J Med2017376181713172228304224
  • LardizabalJADeedwaniaPCBenefits of statin therapy and compliance in high risk cardiovascular patientsVasc Health Risk Manag2010684385320957130
  • FordIMurrayHPackardCJShepherdJMacfarlanePWCobbeSMWest of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention StudyN Engl J Med2007357151477148617928595
  • HoPMMagidDJShetterlySMMedication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery diseaseAm Heart J2008155477277918371492
  • MillerLGHaysRDAdherence to combination antiretroviral therapy: synthesis of the literature and clinical implicationsAIDS Read200010317718510758022
  • KolandaiveluKLeidenBBO’GaraPTBhattDLNon-adherence to cardiovascular medicationsEur Heart J201435463267327625265973
  • BarolettiSdell’orfanoHMedication adherence in cardiovascular diseaseCirculation2010121121455145820351303
  • NunesJPStatins in primary prevention: impact on mortality. A meta-analysis studyMinerva Cardioangiol201765553153828249380
  • RodriguezFMaronDJKnowlesJWViraniSSLinSHeidenreichPAAssociation Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular DiseaseJAMA Cardiol201721475427829091
  • BatesTRConnaughtonVMWattsGFNon-adherence to statin therapy: a major challenge for preventive cardiologyExpert Opin Pharmacother200910182973298519954271
  • WoutersHvan DijkLGeersHCUnderstanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different PatientsPLoS One2016111e014627226808151
  • GragnanoFConcilioCCesaroAP1513Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapyEur Heart J201738suppl_1P1513
  • TorresPRPortillaAJGonzalezMO5PSQ-025 Real-world effectiveness and safety of evolocumab and alirocumabEur J Hosp Pharm201825A176
  • SaborowskiMDölleMMannsMPLeitolfHZenderSLipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohortCardiol J2018251324129168543
  • GraesdalADybvigAReal-life PCSK9 experience: Efficacy, compliance and side effects after one year treatment in familial hypercholesterolemia patientsJ Am Coll Cardiol20187111A1754
  • DentRJoshiRStephen DjedjosCEvolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingSpringerplus2016530027066336
  • BoccaraFDentRRuilopeLValensiPPractical considerations for the use of subcutaneous treatment in the management of DyslipidaemiaAdv Ther20173481876189628717862
  • KaziDSMoranAECoxsonPGCost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular DiseaseJAMA2016316774375327533159
  • ArrietaAHongJCKheraRViraniSSKrumholzHMNasirKUpdated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER TrialJAMA Cardiol20172121369137429049467
  • KosmasCEDejesusEMorceloRGarciaFMontanPDGuzmanELipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapyDrugs Context2017621251129209403
  • National Institute for Health and Care ExcellenceEvolocumab for Treating Primary Hypercholesterolaemia and Mixed DyslipidaemiaLondonNational Institute for Health and Care Excellence2016
  • KormanMWisløffTModelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian settingEur Heart J Cardiovasc Pharmacother201841152228444187
  • LeeTCKaouacheMGroverSAEvaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysisCMAJ Open201862E162E167
  • BaumSJTothPPUnderbergJAJellingerPRossJWilemonKPCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payersClin Cardiol201740424325428328015
  • KaziDSPenkoJOllendorfDACoxsonPGBibbins-DomingoKEffect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 InhibitorsAnn Intern Med20181681289689829610832
  • KosmasCEMuñoz EstrellaASourlasAInclisiran: A New Promising Agent in the Management of HypercholesterolemiaDiseases20186363